Low expression of SMARCC2 is associated with a poor prognosis of glioma and can inhibit the proliferation of glioblastoma cell lines. SMARCC2 can maintain the integrity of the SWI/SNF complex. This evidence concerns the gene SMARCA1 and central nervous system cancer.